Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion

IF 7.6 1区医学 Q1 ONCOLOGY European Journal of Cancer Pub Date : 2025-02-05 DOI:10.1016/j.ejca.2024.115193

Silvia Buriolla , Giulia Zapelloni , Claudia Cipri , Giacomo Pelizzari , Alessandro Follador , Francesco Cortiula

{"title":"Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion","authors":"Silvia Buriolla , Giulia Zapelloni , Claudia Cipri , Giacomo Pelizzari , Alessandro Follador , Francesco Cortiula","doi":"10.1016/j.ejca.2024.115193","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Anaplastic Lymphoma Kinase (<em>ALK</em>) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of <em>ALK</em> inhibitors in advanced DTCs.</div></div><div><h3>Methods</h3><div>We report the case of a striatin (<em>STRN</em>) - <em>ALK</em> translocated advanced thyroid carcinoma.</div><div><em>STRN – ALK</em> translocation was detected by NGS – RNA analysis.</div></div><div><h3>Results</h3><div>A 74-year-old woman received first line alectinib for the treatment of a <em>STRN</em> - <em>ALK</em> translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations.</div><div>The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.</div></div><div><h3>Conclusion</h3><div>Here we report the first case in Europe of <em>STRN</em> - <em>ALK</em> translocated advanced thyroid carcinoma successfully treated with alectinib.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"216 ","pages":"Article 115193"},"PeriodicalIF":7.6000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924018008","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Anaplastic Lymphoma Kinase (ALK) rearrangement is a rare alteration in differentiated thyroid carcinomas (DTCs). Due to its low prevalence, a few evidence are available about the use of ALK inhibitors in advanced DTCs.

Methods

We report the case of a striatin (STRN) - ALK translocated advanced thyroid carcinoma.

STRN – ALK translocation was detected by NGS – RNA analysis.

Results

A 74-year-old woman received first line alectinib for the treatment of a STRN - ALK translocated advanced thyroid carcinoma with symptomatic bilateral lung localizations.

The dose of alectinib was progressively reduced due to the toxicity, but the treatment is still ongoing after 17 months with complete radiological response and clinical benefit.

Conclusion

Here we report the first case in Europe of STRN - ALK translocated advanced thyroid carcinoma successfully treated with alectinib.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿勒替尼治疗伴有STRN - ALK融合的甲状腺乳头状癌。

背景：间变性淋巴瘤激酶（ALK）重排是分化型甲状腺癌（dtc）中一种罕见的改变。由于ALK的低患病率，在晚期dtc中使用ALK抑制剂的证据很少。方法：我们报告一例纹状蛋白(STRN) - ALK易位的晚期甲状腺癌。通过NGS - RNA分析检测STRN - ALK易位。结果：一名74岁妇女接受一线阿勒替尼治疗STRN - ALK易位晚期甲状腺癌伴双侧肺症状性定位。由于毒性，alectinib的剂量逐渐减少，但治疗在17个月后仍在进行，放射学反应完全，临床获益。结论：我们报告了欧洲首例用阿勒替尼成功治疗STRN - ALK易位晚期甲状腺癌的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.